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Recurrences of Hodgkin’s Lymphoma (HL) 5 years after the initial therapy are rare. The aim of this study is to report a single
centre experience of the clinical characteristics, outcome, and toxicity of pts who experienced very late relapses, deﬁned as relapses
that occurred 5 or more years after the achievement of ﬁrst complete remission. Of 532 consecutive pts with classical HL treated
at our Institute from 1985 to 1999, 452 pts (85%) achieved a complete remission.Relapse occurred in 151pts: 135 (29.8%) within
5years and 16 over 5years (3.5%, very late relapses). Very late relapses occurred after a median disease-free interval of 7years
(range: 5–18). Salvage treatment induced complete remission in 14pts (87.5%). At a median of 4years after therapy for very late
relapse, 10pts (63%) are still alive and free of disease and 6 (37%) died (1 from progressive HL, 1 from cardiac disease, 1 from
thromboembolic disease, 1 from HCV reactivation, and 2 from bacterial infection). The probability of failure-free survival at
5years was 75%. The majorityofdeaths are due to treatment-related complications.Therapy regimens for very late relapse HL are
warranted to minimize complications.
1.Introduction
With MOPP/ABVD or ABVD regimens more than 70% of
patients with Hodgkin’s lymphoma (HL) can eﬀectively be
cured. Fewer than 30% of patients, particularly in advanced
stage, may relapse after ﬁrst-line treatment [1–3].
Several clinical and laboratory features have been used to
predict progression-free survival (PFS) and overall survival
(OS), in order to adjust therapy according to the risk of
relapse. These features include age, sex, bulky disease, Ann
Arbor stage IV, bone marrow involvement, anaemia, high
serum levels of lactate dehydrogenase (LDH) or beta2-mi-
croglobulin [4–8], serum interleukin 10, and soluble CD30
[9–12]
Relapses usually occur within the ﬁrst 3 years and a
second complete remission can be achieved using treatment
tailored according to disease extent at relapse [7]a n dp r e v i -
ous treatment [13–16]. Few patients with documented very
late relapses have been closely analyzed in the literature
[17–31].
The aim of this study was to describe the incidence,
clinical presentation, treatment, and outcome of very late
relapse patients (deﬁned as relapse occurring more than 5
years after complete remission) in a series of 532 consecutive
patients with classical HL treated in our institution.
2.Patientsand Methods
From 1985 to 1999, 532 consecutive previously untreated
patients with classical HL were evaluated and treated at the
Hematology Department of the University of Bari, Italy.
All patients were staged according to the Ann Arbor
staging system. Initial evaluation included a complete med-
ical history and physical examination, blood cell count and
serum biochemistry proﬁle, thoracoabdominal computed2 Advances in Hematology
tomography (CT),and bone marrow biopsy at diagnosis and
at relapse.
Response to treatment was deﬁned according to the
International Working Group recommendations [32].
Patientsincompleteremission afterﬁrst-line chemother-
apy were included in this study; a followup was carried out
with clinical examination, blood counts, biochemical tests,
chestX-rayorthoracicCT,andabdominalCTorultrasound,
performed every 3 months during the ﬁrst 2 years after
treatment completion, every 6 months during the following
3 years, and annually thereafter, with a median followup of
12 years.
In all patients who relapsed, a second biopsy was
performed to prove the HL histology of relapse.
3.StatisticalAnalysis
STROBE reporting guidelines for observational studies were
followed [33].
OS and FFS were estimated according to the Kaplan
Meier product limit method.
Overall survival (OS) was measured from the date of the
very laterelapse tothe last visit ordeath.Failure-free survival
(FFS) was calculated from the date of very late relapse
until documented relapse from CR after salvage therapy,




After ﬁrst-line therapy, 452 patients (85%) achieved com-
plete remission (CR). 135 (29.8%) relapsed within 5 years
(102patientsrelapsed <3yearsand 33between 3and5years)
and 16 (3.5%) had very late relapse (>5y e a r s ) .
The distribution of patients and relapse characteristics as
a whole, and divided according to type of relapse, are shown
in Table 1.
The incidence rate of very late relapse after 5-year
disease-free interval was 3.5%
The characteristics and the treatments of the patients in
very late relapse are reported in Table 2.
4.1. Baseline Characteristics of Patients with Very Late
Relapses. The histologies of the 16 patients in very late
relapses were mixed cellularity in 7 (44%) and nodular
sclerosis in 9 (56%). The median age was 37 yrs (16–70); 10
patients were female and 6 were male.
Ten patients (62%%) had stage I-II. B symptoms were
present in 12 patients (75%), and 7 (44%) had bulky
disease. First-line treatment was either standard or accord-
ing to investigational protocols active during the time
the patient was diagnosed. The chemotherapy schedules
used at diagnosis were: ABVD in 1 (6%), MOPP/ABVD
in 8 (50%), and MOPP in 6 (38%). Two patients in
partial remission after MOPP/ABVD underwent high-dose
chemotherapy (BEAM) and autologous stem cell transplan-
tation. Involved-ﬁeld radiotherapy was performed in 11
(69%)patients.The medianradiationdosewas 30Gy(range:
20–36). One patient was treated with radiotherapy alone at
diagnosis.
4.2. Patients Characteristics at Relapse. Median time to late
relapse was 7 years; very late relapses occurred 5 to 18 years
after treatment start (Table 2).
The histologies of very late relapses were in all cases the
same as at diagnosis.
Clinical presentation at relapse demonstrated a supra-
diaphragmatic localization in 6 cases (37%), infradiaphrag-
matic in 8 (50%) and located on both sides in 2 cases (13%).
Bulky nodal disease was observed in 4 patients (25%).
Extranodal disease occurred in 1 patient (6%). B symptoms
were present in 6 patients (37%).
One patient (6%) relapsed on the irradiated ﬁeld (medi-
astinal); 5 (31%) relapsed in sites of bulky disease; in 6
patients (37%), the disease localization was diﬀerent from
the site at diagnosis.
4.3. Treatments of Very Late Relapse and Followup. Treatment
of relapse consisted of chemotherapy alone in 13pts (81%)
and chemotherapy and radiotherapy in 3 (19%). Among 6
patients initially treated with MOPP/ABVD, 4 were retreated
with MOPP/ABVD and 2 received ABVD. All 6 patients
initially treated with MOPP received noncross-resistant
chemotherapy, 5 with ABVD and 1 with MOPP/ABVD.
Both patients who relapsed following MOPP/ABVD plus
BEAM+ASCT received escalated BEACOPP. The only
patientwhorelapsedafterRTalonereceivedVEPEM-B.Only
1 patient received HDT/ASCT as second-line treatment for
very late relapse.
In 4 patients, the chemotherapy regimen was the same
one used as front-line therapy, and all patients achieved a
second complete remission.
6/16patients failed salvage therapy (2 PR and 4 relapses),
and 2 additional patients died in second CR due to throm-
boembolic disease and HCV infection, 2and 29 months after
the conﬁrmation of second CR, respectively.
Of the 16 patients, 14 achieved a second complete remis-
sion (87%) and 9 patients are still alive and free of disease.
Two patients achieved a partial remission.
The median followup was at 32months (range: 8–250),6
patients died (Table 2)
Four patients experienced a second relapse within 1
year from the second complete remission, and they relapsed
in the same sites as at the ﬁrst relapse. One of them
was reinduced to CR with the IEV regimen and is still
in CR with a followup of 24 months, the other three
patients died from toxicity during chemotherapy salvage
treatment (2 from Gram-negative septic shock, 1 of car-
diotoxicity). The patient who died of cardiac failure had
a cumulative dose of anthracycline of 300mg/sqm (the
median cumulative dose of anthracycline for all patients was
300mg/sqm).
In addition, one patient died from thromboembolic
disease, and one died from HCV reactivation without
evidence of HL (Table 2).Advances in Hematology 3
Table 1: Patients characteristics of HL in complete remission after ﬁrst-line chemotherapy.
All Early relapse Late relapse
n 452 135 16
Median age (range) 31 (14–86) 36 (16–79) 37 (16–70)
Male/Female 244/208 81/54 6/10
Stage I-II 271 (60%) 52 (39%) 10 (62%)
Stage III-IV 181 (40%) 83 (61%) 7 (44%)
B symptoms 158 (35%) 58 (43%) 12 (75%)
Histology:
NS 275 (61%) 73 (54%) 9 (56%)
MC 168 (37%) 58 (43%) 7 (44%)
L D 9( 2 % ) 4( 3 % ) 0( 0 % )



























N. pts: 16 12 11 10 10 9
OS
FFS
Figure 1: Overall survival and failure-free survival in 16PTS with
VLR HL. PTS: patients; VLR: very late relapses; FFS: failure-free
survival; OS: overall survival.
Of the two patients in PR, one achieved a CR with the
IEV regimen and is still in CR after 14 months of followup
while the other one died of HL progression.
The estimated OS after late recurrence was 44% at 5
years. The estimated FFS was 75% at 5 years (Figure 1).
5.Discussion
The majority of patients with HL can be cured with
conventional chemotherapy (ABVD), radiotherapy, or both.
Even though HL is curable, approximately 30% of all
patients relapse and eventually die of disease progression or
complications of therapy. [1–3]. Most studies focused on
early relapses should lead to improved ﬁrst-line treatment
approaches and high survival rates. Much less is known
about very late relapse in terms of incidence and outcome
[17–31].
There is no consensus on the deﬁnition of very late
relapse: three or ﬁve years have been proposed in various
reports [17–27]. An interval of 5 years was chosen because
the actuarial rate of relapse appeared to reach a plateau at 5
years [17–27].
The incidence of late relapse reported in previous studies
was variable, from 3.5 to 8 %. This diﬀerence is probably
due to a diﬀerent deﬁnition of the time of relapse (three, ﬁve
years, or more) [17–31].
As the incidence of very late relapse in HL is higher than
the incidence of HL in the general population, it suggests
that this event represents a reactivation of the disease (in
the same sites and with the same histology), rather than the
development of a new HL [22]. The ﬁnding of persistent
HL in autopsies of long survivors who died of apparently
unrelated causes suggests that, for at least some patients with
HL, clinical cure does not always mean the eradication of all
the malignant cells [34]. Some authors have suggested that
the circumstances that impaired the immune system may
cause the recurrence [35]. Atleast part of thelate recurrences
of HLmight bedenovo emerging malignancies in patients at
elevated genetic risk for developing HL [36]. The persistence
of the same viral strain in early and very late relapse of
E p s t e i n - B a r rv i r u si se v i d e n c et h a ti nH Ls u c hr e l a p s e sa r e
related to a single residual tumor cell clone [37, 38].
Herman et al. [25] reported that the actuarial risk of
relapse after a 3-year disease-free interval was 13%. These
investigators found that the occurrence of late relapse was
signiﬁcantly related to stage I disease and the nodular
sclerosishistologicsubtype.Anotherreport, bytheEuropean
Organization for Research and Treatment of Cancer [22],
showed a 3.5% incidence of very late relapse after a 5-year
disease-free interval. That study showed that the incidence
of late relapses was signiﬁcantly correlated with male sex, B
symptoms, mediastinal involvement, and treatment modal-
ity. The authors found that HL patients who experience a
very late relapse have a similar survival to patients who are
continuouslydisease-free. Theactuarialincidenceofverylate
relapse at10and15yearsinearlystagepatientswas4.8%and
8.3%, respectively. Similarly, the actuarial incidence of very
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4.4% and 8.0%, respectively, as reported by Vassilakopoulos
et al. [27].
The investigators observed that patients with LH more
often developed very late relapse when they were treated
with less intensive therapy. In our series, two patients
had very late relapse after high-dose chemotherapy and
autologous stem cell transplantation. Another report [20]
of patients in early stage HL revealed 4.6% of very late
relapse (more than 4 years). These investigators found that
these patients had better survival than did patients with early
relapse.
Bodis et al. [22] reported that very late relapses in
early stage patients were more frequent in males with B
symptoms at diagnosis and mediastinal involvement, who
had been treated with radiotherapy only (versus combined
modality). Vassilakopoulos et al. [27], in an analysis of
all stages, reported that very late relapses were more fre-
quent in patients with more extensive disease at diagnosis,
nonnodular sclerosing histology, who had been treated with
chemotherapyonly(versuscombinedmodality).AlsoBrierly
et al. [20] found age and B symptoms as predictors for late
relapse in early stage patients.
The fact that in our study, 14 patients (87%) had stage I
or II disease at the time of very late relapse could be due to
the continuous followup of patients in complete remission.
No histological characteristics have been found to corre-
late with very late relapse risk, but more cases are necessary
to draw deﬁnitive conclusions. There is no accurate means
to identify patients at risk of very late relapse, and there is
no absolutely safe point at which an individual patient may
be considered cured of HL and at no risk of very late relapse
[17–31].
In our study 11/16 patient had radiotherapy as part of
their initial therapy, but only one patient relapsed in the
radiotherapy ﬁeld. Radiotherapy seems to be an important
issue in preventing late relapse.
Patients who relapse within the ﬁrst 3 years have more
aggressive disease, and patients who relapse late have a more
indolent disease that responds to further therapy [21, 22].
Very late relapse is adequately reinduced to complete
remission by a second course of the primary treatment
regimen, and so are still curable with conventional treat-
ment, as documented by our 5 patients treated with the
same therapy, who achieved a second complete remission.
In fact, 5/6 patients treated with the same regimen (4
MOPP/ABVD to MOPP/ABVD, 2 MOPP/ABVD to ABVD)
achieved a second CR, but 2/5 relapsed, and one is not
evaluable for relapse due to early death. Thus the data
presented in this study support that the administration of
the same drugs is eﬀective in inducing a second CR, but
its potential in inducing long-term remissions (cure?) is
questionable.
However, despite the high percentage of complete remis-
sions (87%), 4 patients relapsed (second relapse) early (<1
years) while 4 patients died of toxicity (1 from cardiac
disease, 1 from HCV reactivation, and 2 from gram negative
sepsis). Another TRM due to pulmonary thromboembolism
was observed in second complete remission, 2 months after
the completion of chemotherapy.
In conclusion, very late relapse occurs in a small number
of patients with HL, which emphasizes the need for contin-
uous followup. Very late relapse is associated with a better
survival than relapse occurring within the ﬁrst 5 years from
the time of diagnosis [20, 22]. Unfortunately, the majority of
deaths of patients in very late relapse are related to treatment
complications while deaths due to HL are unusual. Future
treatment regimens for HL, including very late relapse, need
to be designed to minimize complications.
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